4
Changes in Ownership
IONIS PHARMACEUTICALS INC Filed Acc 0000874015-23-000241
Director sold 117,638 shares at an average $50.48 ($5,938,129)
- Director acquired 117,638 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
PARSHALL B LYNNE · Director
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-12-26 | Exercise or conversion : show line 1 in the form 10b5-1 | +25,113 | $47.34 | $1,188,849 | 107,701 | D |
| 2023-12-26 | Sale : show line 2 in the form 10b5-1 | −25,113 | $51.46 | $1,292,390 | 82,588 | D |
| 2023-12-27 | Exercise or conversion : show line 3 in the form 10b5-1 | +50,000 | $47.34 | $2,367,000 | 132,588 | D |
| 2023-12-27 | Sale : show line 4 in the form 10b5-1 | −50,000 | $50.23 | $2,511,515 | 82,588 | D |
| 2023-12-28 | Exercise or conversion : show line 5 in the form 10b5-1 | +42,525 | $47.34 | $2,013,134 | 125,113 | D |
| 2023-12-28 | Sale : show line 6 in the form 10b5-1 | −42,525 | $50.19 | $2,134,223 | 82,588 | D |
| Open-market sales · 117,638 sh · avg $50.48 · $5,938,129 | ||||||
Table II: Derivative
3 lines| Date | Transaction | Shares | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| 2023-12-26 | Exercise or conversion : show line 7 in the form 10b5-1 Non-Qualified Stock Option (right to buy) | −25,113 | $47.34 | 2024-01-02 | 25,113 | 92,525 | D |
| 2023-12-27 | Exercise or conversion : show line 8 in the form 10b5-1 Non-Qualified Stock Option (right to buy) | −50,000 | $47.34 | 2024-01-02 | 50,000 | 42,525 | D |
| 2023-12-28 | Exercise or conversion : show line 9 in the form 10b5-1 Non-Qualified Stock Option (right to buy) | −42,525 | $47.34 | 2024-01-02 | 42,525 | 0 | D |
Loading xslF345X05/edgardoc.xml…